8-biphenyl-4-ylmethyl-6,6a,7,8,9,10-hexahydro-4H-4,8,10a-triaza-acephenanthrylene | 1315512-34-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-biphenyl-4-ylmethyl-6,6a,7,8,9,10-hexahydro-4H-4,8,10a-triaza-acephenanthrylene
• 英文别名: 5-[(4-Phenylphenyl)methyl]-2,5,11-triazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),9,12(16),13-tetraene
• CAS: 1315512-34-5
• 化学式: C₂₆H₂₅N₃
• 分子量: 379.505
• InChiKey: LBALZQQRFZMPJO-UHFFFAOYSA-N

物化性质

• 沸点：
  592.7±50.0 °C(predicted)
• 密度：
  1.28±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  22.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6,6a,7,8,9,10-hexahydro-4H-pyrazino[1,2-a]pyrrolo[4,3,2-de]quinoline 、 4-溴甲基联苯 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 18.0h， 生成 8-biphenyl-4-ylmethyl-6,6a,7,8,9,10-hexahydro-4H-4,8,10a-triaza-acephenanthrylene
  参考文献：
  名称：

  Novel Aza-analogous Ergoline Derived Scaffolds as Potent Serotonin 5-HT₆ and Dopamine D₂ Receptor Ligands.

  摘要：

  By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D-2 and serotonin S-HT6 receptor subtype, respectively. While the S-HT6 ligands were antagonists, the D-2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.

  DOI：

  10.1021/jm5003759

文献信息

• [EN] NOVEL 6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACEPHENANTHRYLENE DERIVATIVES AS DOPAMINE D2 LIGANDS<br/>[FR] NOUVEAUX DÉRIVÉS 6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACÉPHÉNANTHRYLÈNE EN TANT QUE LIGANDS DES RÉCEPTEURS D2 DE LA DOPAMINE
  申请人：LUNDBECK & CO AS H

  公开号：WO2011088838A1

  公开（公告）日：2011-07-28

  This invention is directed to compounds, which are dopamine D2 ligands. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I or formula II, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I or formula II, or a pharmaceutically acceptable salt thereof.

  这项发明涉及多巴胺D2受体配体化合物。该发明提供了一种包括该发明化合物的治疗有效量和药用载体的药物组合物。本发明还提供了制备式I或式II化合物或其药用可接受盐的方法。本发明还提供了一种治疗患有神经退行性疾病的受试者的方法，包括向受试者施用式I或式II化合物或其药用可接受盐的治疗有效量。本发明还提供了一种治疗患有精神障碍的受试者的方法，包括向受试者施用式I或式II化合物或其药用可接受盐的治疗有效量。
• Novel Aza-analogous Ergoline Derived Scaffolds as Potent Serotonin 5-HT₆ and Dopamine D₂ Receptor Ligands.
  作者：Niels Krogsgaard-Larsen、Anders A. Jensen、Tenna J. Schrøder、Claus. T. Christoffersen、Jan Kehler

  DOI：10.1021/jm5003759

  日期：2014.7.10

  By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D-2 and serotonin S-HT6 receptor subtype, respectively. While the S-HT6 ligands were antagonists, the D-2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.